Drug updated on 11/1/2024
| Dosage Form | Injection (intravenous; 148 MBq to 1,225 MBq [4 mCi to 33.1 mCi]) |
| Drug Class | Radioactive diagnostic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging
- In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation
- Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
Latest News
Summary
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- Radiolabeled choline and [(68)Ga]PSMA-11 demonstrate a prognostic role in predicting radiotherapy response and survival outcomes in prostate cancer patients; however, their efficacy in systemic therapies (e.g., docetaxel, enzalutamide, abiraterone acetate) remains inadequately supported by data.
- In the initial staging of prostate cancer, PET radiomics provides added predictive value for lesion detection and tumor grading, with radiomic features such as "kurtosis," "grey-level uniformity," and "HLL wavelet mean" identified as predictive markers.
- PSMA-radiotracers, including [(68)Ga]PSMA-11, [(18)F]PSMA-1007, and [(18)F]DCFPyl, exhibit superior detection rates over choline-radiotracers and fluciclovine in recurrent prostate cancer, with no significant detection differences observed among the PSMA-radiotracers.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Choline C 11 Injection (choline C 11) Prescribing Information. | 2024 | Mayo Clinic Radiology, Rochester, MN |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature | 2022 | Cancers |
| Additional Value of PET Radiomic Features for the Initial Staging of Prostate Cancer: A Systematic Review from the Literature | 2021 | Cancers |
| Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis | 2021 | European journal of nuclear medicine and molecular imaging |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. | 2023 | European Association of Urology |
| Optimum imaging strategies for advanced prostate cancer: ASCO guideline. | 2020 | Journal of Clinical Oncology |